Antiproliferative effect of Newcastle disease virus strain D90 on human lung cancer cell line A549

Oncology Research

Volumn 19, Issue 7, 2011, Pages 323-333

  Fu, Fang ^a   Zhao, Ming ^b   Yang, Yu Ju ^c   Tong, Guang Zhi ^a   Yang, Bao Feng ^b   Song, Chun ^b   Li, Xi ^a  

^a INSTITUTE OF PLANT PROTECTION   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c HARBIN UNIVERSITY   (China)

Author keywords

Apoptosis; Cell line A549; Hemaglutinin; Newcastle disease virus (NDV); Non small cell lung cancer

Indexed keywords

D 90; D 93; ONCOLYTIC VIRUS; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL STRUCTURE; CELL VIABILITY; CHICKEN; CONTROLLED STUDY; DNA FRAGMENTATION; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; LUNG NON SMALL CELL CANCER; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 80051861228     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504011X13079697132880     Document Type: Article

References (27)

1. Capua, I.; Alexander, D. J. Avian influenza and Newcastle disease: A field and laboratory manual. Milan: Springer; 2009.
2. Haseley, A.; Alvarez-Breckenridge, C.; Chaudhury, A. R.; Kaur, B. Advances in oncolytic virus therapy for glioma. Recent Pat. CNS Drug Discov. 4:1-13; 2009.
3. Reichard, K. W.; Lorence, R. M.; Cascino, C. J.; Peeples, M. E.; Walter, R. J.; Fernando, M. B.; Reyes, H. M.; Greager, J. A. Newcastle disease virus selectively kills hutolerability man tumor cells. J. Surg. Res. 52:448-453; 1992.
4. Lorence, R. M.; Reichard, K. W.; Katubig, B. B.; Reyes, H. M.; Phuangsab, A.; Mitchell, B. R.; Cascino, C. J.; Walter, R. J.; Peeples, M. E. Complete regression of huported man neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J. Natl. Cancer Inst. 86: 1228-1233; 1994.
5. Vigil, A.; Park, M. S.; Martinez, O.; Chua, M. A.; Xiao, S.; Cros, J. F.; Martínez-Sobrido, L.; Woo, S. L.; Garcíatured Sastre, A. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res. 67: 8285-8292; 2007.
6. Ravindra, P. V.; Tiwari, A. K.; Sharma, B.; Chauhan, R. S. Newcastle disease virus as an oncolytic agent. Indian J. Med. Res. 130:507-513; 2009.
7. Elankumaran, S.; Chavan, V.; Qiao, D.; Shobana, R.; Moorkanat, G.; Biswas, M.; Samal, S. K. Type I interand feron-sensitive recombinant newcastle disease virus for oncolytic virotherapy. J. Virol. 84:3835-3844; 2010.
8. Elankumaran, S.; Rockemann, D.; Samal, S. K. Newcastle disease virus exerts oncolysis by both intrinsic and extrinof sic caspase-dependent pathways of cell death. J. Virol. 80: 7522-7534; 2006.
9. Freeman, A. I.; Zakay-Rones, Z.; Gomori, J. M.; Linetsky, E.; Rasooly, L.; Greenbaum, E.; Rozenman-Yair, S.; Panet, A.; Libson, E.; Irving, C. S.; Galun, E.; Siegal, T. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol. Ther. 13:221-228; 2006.
10. Csatary, L. K.; Bakács, T. Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade gli- oblastoma. JAMA 281:1588-1589; 1999.
11. Csatary, L. K.; Gosztonyi, G.; Szeberenyi, J.; Fabian, Z.; Liszka, V.; Bodey, B.; Csatary, C. M. MTH-68/H oncothe lytic viral treatment in human high-grade gliomas. J. Neusitivity rooncol. 67:83-93; 2004.
12. Lorence, R. M.; Roberts, M. S.; O'Neil, J. D.; Groene, W. S.; Miller, J. A.; Mueller, S. N.; Bamat, M. K. Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus. Curr. Cancer Drug Targets 7:157-167; 2007.
13. Sui, H.; Bai, Y.; Wang, K.; Li, X.; Song, C.; Fu, F.; Zhang, Y.; Li, L. The anti-tumor effect of Newcastle disease virus HN protein is influenced by differential subcelinduction lular targeting. Cancer Immunol. Immunother. 59:989-999; 2010.
14. OIE manual of standards for diagnostic tests and vaccines. List A and B diseases of mammals, birds and bees. Paris: Office International des Epizooties; 1996.
15. Yin, Z.; Liu, J. H. Animal virology. Beijing: Science Press; 1997.
16. Meng, S.; Bai, H.; Hu, M.; Liu, W.; Wang, L.; Wu, Y.; Jiao, X.; Fan, J. Mechanisms of in vitro anti-tumor effects of a Newcastle disease virus. Wei Sheng Wu Xue Bao 49: 512-517; 2009. (in Chinese)
17. Song, K. Y.; Wong, J.; Gonzalez, L.; Sheng, G.; Zamarin, D.; Fong, Y. Antitumor efficacy of viral therapy using ge- netically engineered Newcastle disease virus [NDV(F3aa)- GFP] for peritoneally disseminated gastric cancer. J. Mol. Med. 88:589-596; 2010.
18. Guo, Z. S.; Thorne, S. H.; Bartlett, D. L. Oncolytic viro- therapy: Molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim. Biophys. Acta 1785:217-231; 2008.
19. Altomonte, J.; Marozin, S.; Schmid, R. M.; Ebert, O. En- gineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma. Mol. Ther. 18: 275-284; 2010.
20. Silberhumer, G. R.; Brader, P.; Wong, J.; Serganova, I. S.; Gönen, M.; Gonzalez, S. J.; Blasberg, R.; Zamarin, D.; Fong, Y. Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of ma- Onlignant pleural mesothelioma. Mol. Cancer Ther. 9:2761-2769; 2010.
21. Wong, J.; Schulman, A.; Kelly, K.; Zamarin, D.; Palese, P.; Fong, Y. Detection of free peritoneal cancer cells in gastric cancer using cancer-specific Newcastle disease vi- rus. J. Gastrointest. Surg. 14:7-14; 2010.
22. Jarahian, M.; Watzl, C.; Fournier, P.; Arnold, A.; Djandji, D.; Zahedi, S.; Cerwenka, A.; Paschen, A.; Schirrmacher, V.; Momburg, F. Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase. J. Virol. 83:8108-8121; 2009.
23. Garber, K. China approves world's first oncolytic virus therapy for cancer treatment. J. Natl. Cancer Inst. 98:298-300; 2006.
24. Schirrmacher, V.; Ahlert, T.; Pröbstle, T.; Steiner, H. H.; Herold-Mende, C.; Gerhards, R.; Hagmüller, E. Immunization with virus-modified tumor cells. Semin. Oncol. 25: 677-696; 1998.
25. Cassel, W. A.; Murray, D. R.; Phillips, H. S. A phase II study on the postsurgical management of Stage II malig- nant melanoma with a Newcastle disease virus oncolysate. Cancer 52:856-860; 1983.
26. Cassel, W. A.; Murray, D. R. A ten-year follow-up on stage II malignant melanoma patients treated postsurgiease cally with Newcastle disease virus oncolysate. Med. Oncol. Tumor. Pharmacother. 9:169-171; 1992.
27. Bar-Eli, N.; Giloh, H.; Schlesinger, M.; Zakay-Rones, Z. Preferential cytotoxic effect of Newcastle disease virus on lymphoma cells. J. Cancer Res. Clin. Oncol. 122:409-415; 1996.